Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 215

recruiting
3 973
countries
28
conditions
2 104

10 286 trials match your criteria

Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ademetionine

Study on Ruxolitinib and Methoxsalen for Patients with Steroid-Refractory Chronic Graft-versus-Host Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen

Study on the Safety of CD19 CAR-T Cells, Cyclophosphamide, and Fludarabine in Adults with Refractory or Relapsed Acute Myeloid Leukemia Expressing CD19

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Weaning failure

Recruiting

Study Comparing Non-Invasive Ventilation and High Flow Oxygen Therapy for Patients at Risk of Breathing Support Failure After Ventilator Removal

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen

Study on the Use of 68Ga-FAPI-46 and Fludeoxyglucose (18F) for Diagnosing Pleural Mesothelioma in Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Study of dabrafenib and trametinib combination therapy before and after surgery in patients with BRAF-mutated anaplastic thyroid cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dabrafenib

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat

Study on Letermovir for Preventing Cytomegalovirus in Stem Cell Transplant Patients with CMV-Positive Donors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Letermovir

Study on Heart Function Changes in Cancer Patients Treated with Nivolumab or Pembrolizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Study of Axitinib and Etoposide for Children and Young Adults with Refractory or Relapsing Medulloblastoma and Ependymoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Axitinib
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

Study on Ruxolitinib for Treating Inclusion Body Myositis in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.